

Corresponding author(s):	Xinyu Zhao
Last updated by author(s):	Jan 3 2019

# **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Sta	atistics							
For	all statistical anal	yses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.						
n/a	Confirmed	firmed						
	The exact sa	ample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement						
	X A statemen	t on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly						
	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.							
	A description	on of all covariates tested						
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons							
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)							
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable.							
$\times$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings							
$\times$	For hierarch	nical and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
$\times$	Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated							
	1	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
So	ftware and	code						
Poli	cy information ab	pout <u>availability of computer code</u>						
D	ata collection	NIS-Elements for confocal imaging (Nikon); pClamp 10.4 for whole-cell patch-clamp recordings (Molecular Devices); ImageJ for imaging analysis (RRID: SCR_003070); Quantity One for imaging regular genotyping gels (BioRad); Fusion Accuscan program for open field tests (Omnitech Electronics)						
D	ata analysis	Neurolucida, StereoInvestigator, Image J, Igor Pro, STAR v2.5.3a, EBSeq v1.18.0, PANTHER, WEbGESTALT, SPSS v22, GraphPad 6						
Far :	nanusarinta utilizina a	ustom alreaditions are afficient that are control to the account but not ust described in published literature afficiency must be made a mileble to editors (reviewed						

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Submission of sequencing data to GEO with GEO # GSE117111

Field-specific reporting
Please select the one below that is the best fit for your research. If you are no

rieiu-spe	ecinc reporting
Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of t	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces study design
All studies must dis	close on these points even when the disclosure is negative.
Sample size	Sample size was used as dictated by literature on similar studies.
Data exclusions	No data were excluded from the analyses.
Replication	Replication of experiments was successful.
Randomization	All cells analyzed were randomly selected from in vivo and in vitro samples.
Blinding	Quantifications were performed by experimenters who were blind to the identity of the sample.
Donortin	a for specific materials, systems and methods
<u> </u>	g for specific materials, systems and methods
	on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ted is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & exp	perimental systems Methods
n/a Involved in th	· · · · · · · · · · · · · · · · · · ·
Antibodies	
Palaeontol	
Animals an	d other organisms
Human res	search participants
Clinical dat	
A m tila a di a a	
<u>Antibodies</u>	
Antibodies used	The primary antibodies used: chicken anti-GFP (1:500, Invitrogen, Carlsbad, CA, #A10262), rat anti-Ki67 (SolA15) (1:500, eBioscience, 14-5698, San Diego, CA, USA), rabbit anti-GFAP (1:2000, DAKO, #Z0334, Carpinteria, CA, USA), chicken anti-Nestin (1:500, Aves Labs, #NES0407, Tigard, OR, USA), rabbit anti-Doublecortin (1:500, Cell Signaling Technology, #4604S, Beverly, MA, USA), rabbit anti-cleaved caspase-3 (Asp175) (1:500, Cell Signaling, #9661, Danvers, MA, USA), mouse anti-NeuN (clone A60) (1:500, Millipore, MAB377, Billerica, MA, USA), rabbit anti-S100β (1:1000, Dako, Z0334, Carpinteria, CA, USA), mouse anti-FMRP (clone 1C3) (1:500, Millipore, MAB2160), mouse anti-Nitrotyrosine (3986) (1:500, Santa Cruz Biotechnology, sc-32757, Texas, DA, USA), mouse anti-Huntingtin (3E10) (1:500, Santa Cruz Biotechnology, sc-47757, Texas, DA, USA), mouse anti-Opa1 ([EPR11057(B)]) (1:1000, Abcam, ab157457, Cambridge, MA), mouse anti-Mfn1 (3C9) (1:1000, Abcam, ab57602, Cambridge, MA), rabbit anti-Mfn2 (1:500, Proteintech, 12186-1-AP, Rosemont, IL), rabbit anti-Drp1 (EPR19274) (1:1000, Abcam, ab184247, Cambridge, MA) and mouse anti-FMRP (7G1-1) (1:500, DSHB, 7F1-1-C, University of Iowa, Department of Biology, IA). Fluorescent secondary antibodies for IHC used by 1:500 dilution: goat anti-chicken-488 (A11039, Invitrogen), goat anti-mouse 568 (A11004, Invitrogen), goat anti-rabbit 647 (A21245, Invitrogen), donkey anti-goat 568 (A11057, Invitrogen), donkey anti-rabbit 568 (A11051, Invitrogen), goat anti-mouse 647 (A21235, Invitrogen), goat anti-rabbit 568 (A11011, Invitrogen), and donkey anti-mouse 647 (A31571, Invitrogen). Fluorescent secondary antibodies for WB used by 1:5000 dilution: IRDye 800CW Goat anti-Mouse IgG (H+L) (925-32210, LiCore), IRDye 800CW Goat anti-Rabbit IgG (H+L) (925-68021), LiCore), IRDye 680LT Goat anti-Rabbit IgG (H+L) (925-68021), LiCore)
Validation	primary antibodies:

- 1. chicken anti-GFP (Invitrogen, Carlsbad, CA, #A10262), mouse, IHC, validation on manufacturer's website: https:// www.thermofisher.com/antibody/product/GFP-Tag-Antibody-Polyclonal/A10262#/IHC-content.
- 2. rat anti-Ki67 (SoIA15) (1:500, eBioscience, 14-5698, San Diego, CA, USA), mouse, IHC, validation on manufacturer's website: https://www.thermofisher.com/antibody/product/Ki-67-Antibody-clone-SolA15-Monoclonal/14-5698-82.
- 3. rabbit anti-GFAP (1:2000, DAKO, #Z0334, Carpinteria, CA, USA), mouse, IHC, validation on publication: PMID: 21516088.
- 4. chicken anti-Nestin (1:500, Aves Labs, #NES0407, Tigard, OR, USA), mouse, IHC, validation on publication: PMID: 28100736.

5. rabbit anti-Doublecortin (1:500, Cell Signaling Technology, #4604S, Beverly, MA, USA), mouse, IHC, validation on manufacturer's website: https://www.cellsignal.com/products/primary-antibodies/doublecortin-antibody/4604.
6. rabbit anti-cleaved caspase-3 (Asp175) (1:500, Cell Signaling, #9661, Danvers, MA, USA), mouse, IHC, validation on manufacturer's website: https://www.cellsignal.com/products/primary-antibodies/cleaved-caspase-3-asp175-antibody/9661.
7. mouse anti-NeuN (clone A60) (1:500, Millipore, MAB377, Billerica, MA, USA), mouse, IHC, validation on manufacturer's website: http://www.emdmillipore.com/US/en/product/Anti-NeuN-Antibody-clone-A60,MM\_NF-MAB377?ReferrerURL=https/3A%2F%2Fwww.google.com%2F&bd=1.

- 8. rabbit anti-S100ß (1:1000, Dako, Z0334, Carpinteria, CA, USA), validation on publication: PMID: 28100736.
- 9. mouse anti-FMRP (clone 1C3) (1:500, Millipore, MAB2160), mouse, IHC, validation on manufacturer's website: http://www.emdmillipore.com/US/en/product/Anti-Fragile-X-Mental-Retardation-Protein-Antibody-clone-1C3,MM\_NF-MAB2160. 10. mouse anti-Nitrotyrosine (39B6) (1:500, Santa Cruz Biotechnology, sc-32757, Texas, DA, USA), mouse, IHC, validation on manufacturer's website: https://www.scbt.com/scbt/product/nitrotyrosine-antibody-39b6.
- 11. mouse anti-Huntingtin (3E10) (1:500, Santa Cruz Biotechnology, sc-47757, Texas, DA, USA), mouse, IHC, validation on manufacturer's website: https://www.scbt.com/scbt/product/huntingtin-antibody-3e10.
- 12. mouse anti-Opa1 ([EPR11057(B)]) (1:1000, Abcam, ab157457, Cambridge, MA), mouse, WB, validation on manufacturer's website: https://www.abcam.com/opa1-antibody-epr11057b-ab157457.html.
- 13. mouse anti-Mfn1 (3C9) (1:1000, Abcam, ab57602, Cambridge, MA), mouse, WB, validation on manufacturer's website: https://www.abcam.com/mitofusin-1-antibody-3c9-ab57602.html.
- 14. rabbit anti-Mfn2 (1:500, Proteintech, 12186-1-AP, Rosemont, IL), mouse, WB, validation on manufacturer's website: https://www.ptglab.com/products/MFN2-Antibody-12186-1-AP.htm.
- 15. rabbit anti-Drp1 (EPR19274) (1:1000, Abcam, ab184247, Cambridge, MA), mouse, WB, validation on manufacturer's website: https://www.abcam.com/drp1-antibody-epr19274-ab184247.html.
- 16. mouse anti-FMRP (7G1-1) (1:500, DSHB, 7F1-1-C, University of Iowa, Department of Biology, IA), mouse, IP, validation on manufacturer's website: http://dshb.biology.uiowa.edu/7G1-1.

# Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

Human FXS iPSC line (FX11-7) was published. GM1 (GM00498-4) iPSCs were generated from fibroblasts from an apparently healthy 3 year old male obtained from Coriell (GM00498) using the same Yamanaka method. More details are provided in "Supplementary Methods" subheading "Human cell culture, neural differentiation and transplantation".

Authentication

Authentication includes confirmation of correct karyotype, pluripotency, and absence of pathogen or mycoplasma contamination. Human FXS iPSC line (FX11-7) has been fully authenticated by our lab and WiCell (https://www.wicell.org/) and has been published (Doers et al 2014). GM1 (GM00498-4) iPSC line has been authenticated for pluripotency, karyotype, mycoplasma by our lab and WiCell, and the test for human pathogen is currently being performed by WiCell before distribution to scientific community.

Mycoplasma contamination

The cell lines used in this study were tested negative for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

No misidentified lines were used in this study.

# Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

Mice, C57BL/6, male and female, different ages according to experiments (P0 up to 4 months old)

Wild animals

No wild animals were used in this study

Field-collected samples

No field-collected samples were used in this study

Ethics oversight

We performed all procedures involving live mice in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the protocols approved by the University of Wisconsin-Madison Animal Care and Use Committee (IACUC). We performed all experiments involving human iPSCs based on the guideline of University of Wisconsin Stem Cell Research Oversight (SCRO) committee. We performed all experiments involving biohazard materials based on protocols approved by University of Wisconsin Biosafety (BIO) committee.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

#### **Plots**

Confirm that:

X	The axis	labels state the	marker and	fluorochrome	used (e.g.	CD4-FITC).
---	----------	------------------	------------	--------------	------------	------------

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

DG tissue were isolated from 6-7 weeks old Fmr1-/y; Dcx-DsRed mice and their WT littermates.

Instrument

Becton Dickinson FACS Aria II

Software

StereoInvestigator software (MicroBrightField)

Cell population abundance

All cell populations were isolated into single cells using a Becton Dickinson FACS Aria II contained in a Biosafety Carbinet using 20 psi pressure and 100-μm nozzle aperture. 10,000 total alive or Dcx-DsRed+ alive Cells were collected directly in Trizol.

Gating strategy

Gates were set manually by using control samples (same types of cells isolated from mice without Dcx-DsRed transgene).

☑ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.